NEW YORK, July 9 – Index Ventures has closed a new $300 million fund to target information technology and life sciences companies in Europe, the firm said Monday.

A spokeswoman said the firm would target life science businesses developing post-genomic platforms, therapeutics, and nanotechnology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.